Sign up for free newsletter

 

New York-based Signal Capital Management, a hybrid hedge fund and private equity firm, has appointed Dr. Roger von Hanwehr to its board of directors in the capacity of vice chairman.

Dr. von Hanwehr is the chief executive of Solus, a firm developing energy technologies, and is a co-founder of Arcxeon, a global technology, financial, and strategic consulting firm

He is an internationally recognised authority on biological, chemical and radiological defence; biomedicine; radiosurgery; renewable energy; space based technology; and the application of nanotechnology to these fields.

Dr. von Hanwehr teaches the Biodefense Colloquia in the biotechnology programme at Georgetown University, and is widely published.

He has been an advisor to the IST group at SDIO and BMDO and was a fellow at the Laboratory for Experimental Brain Research of the University of Lund, Sweden, where he specialized in tumour immunoncology, neuroimmunology and neurometabolism.

Dr. von Hanwehr will work with Signal to evaluate investment opportunities globally.


Subscribe to free daily newsletter
latestjobs
Senior Pre-Sales Architect – Big Data/Hadoop

Fri, 01 May 2015 00:00:00 GMT

Algorithmic Trading Developer - C++, Linux, Python

Fri, 01 May 2015 00:00:00 GMT

Director - Core Java Architect - Equities

Fri, 01 May 2015 00:00:00 GMT

events
12 hours 59 min from now - San Diego
1 day 12 hours from now - New York
2 days 12 hours from now - London
specialreports